1 Aktas T, Avsar Ilik I, Maticzka D, Bhardwaj V, Pessoa Rodrigues C, Mittler G et al. DHX9 suppresses RNA processing defects originating from the Alu invasion of the human genome. Nature 2017; 544: 115-119.
2 Amin EM, Liu Y, Deng S, Tan KS, Chudgar N, Mayo MW et al. The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK. Sci Signal 2017; 10.
3 Anadon C, Guil S, Simo-Riudalbas L, Moutinho C, Setien F, Martinez-Cardus A et al. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis. Oncogene 2016; 35: 4407-4413.
4 Bhate A, Sun T, Li JB. ADAR1: A New Target for Immuno-oncology Therapy. Mol Cell 2019; 73: 866-868.
5 Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC, Jr., Beral V et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 2015; 15: 668-679.
6 Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
7 Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD et al. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015; 75: 628-634.
8 Chakraborty P, Huang JTJ, Hiom K. DHX9 helicase promotes R-loop formation in cells with impaired RNA splicing. Nat Commun 2018; 9: 4346.
9 Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut 2014; 63: 832-843.
10 Chan TH, Qamra A, Tan KT, Guo J, Yang H, Qi L et al. ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. Gastroenterology 2016; 151: 637-650 e610.
11 Chen L, Chen JY, Huang YJ, Gu Y, Qiu J, Qian H et al. The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. Mol Cell 2018; 69: 412-425 e416.
12 Chung H, Calis JJA, Wu X, Sun T, Yu Y, Sarbanes SL et al. Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown. Cell 2018; 172: 811-824 e814.
13 Cristini A, Groh M, Kristiansen MS, Gromak N. RNA/DNA Hybrid Interactome Identifies DXH9 as a Molecular Player in Transcriptional Termination and R-Loop-Associated DNA Damage. Cell Rep 2018; 23: 1891-1905.
14 Forni D, Mozzi A, Pontremoli C, Vertemara J, Pozzoli U, Biasin M et al. Diverse selective regimes shape genetic diversity at ADAR genes and at their coding targets. RNA Biol 2015; 12: 149-161.
15 Fritzell K, Xu LD, Lagergren J, Ohman M. ADARs and editing: The role of A-to-I RNA modification in cancer progression. Semin Cell Dev Biol 2018; 79: 123-130.
16 Fritzell K, Xu LD, Otrocka M, Andreasson C, Ohman M. Sensitive ADAR editing reporter in cancer cells enables high-throughput screening of small molecule libraries. Nucleic Acids Res 2019; 47: e22.
17 Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun 2018; 9: 5450.
18 Hamperl S, Bocek MJ, Saldivar JC, Swigut T, Cimprich KA. Transcription-Replication Conflict Orientation Modulates R-Loop Levels and Activates Distinct DNA Damage Responses. Cell 2017; 170: 774-786 e719.
19 Hong H, An O, Chan THM, Ng VHE, Kwok HS, Lin JS et al. Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancer. Nucleic Acids Res 2018; 46: 7953-7969.
20 Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 2019; 565: 43-48.
21 Jiang Q, Isquith J, Zipeto MA, Diep RH, Pham J, Delos Santos N et al. Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation. Cancer Cell 2019; 35: 81-94 e87.
22 Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020; 21: 957-968.
23 Li Y, Banerjee S, Goldstein SA, Dong B, Gaughan C, Rath S et al. Ribonuclease L mediates the cell-lethal phenotype of double-stranded RNA editing enzyme ADAR1 deficiency in a human cell line. Elife 2017; 6.
24 Liddicoat BJ, Piskol R, Chalk AM, Ramaswami G, Higuchi M, Hartner JC et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 2015; 349: 1115-1120.
25 Liu H, Golji J, Brodeur LK, Chung FS, Chen JT, deBeaumont RS et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat Med 2019; 25: 95-102.
26 Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 2013; 5.
27 Nguyen HD, Leong WY, Li W, Reddy PNG, Sullivan JD, Walter MJ et al. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. Cancer Res 2018; 78: 5363-5374.
28 Ota H, Sakurai M, Gupta R, Valente L, Wulff BE, Ariyoshi K et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing. Cell 2013; 153: 575-589.
29 Qi L, Song Y, Chan THM, Yang H, Lin CH, Tay DJT et al. An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer. Nucleic Acids Res 2017; 45: 10436-10451.
30 Qin YR, Qiao JJ, Chan TH, Zhu YH, Li FF, Liu H et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res 2014; 74: 840-851.
31 Rossetti C, Picardi E, Ye M, Camilli G, D'Erchia AM, Cucina L et al. RNA editing signature during myeloid leukemia cell differentiation. Leukemia 2017; 31: 2824-2832.
32 Sakurai M, Shiromoto Y, Ota H, Song C, Kossenkov AV, Wickramasinghe J et al. ADAR1 controls apoptosis of stressed cells by inhibiting Staufen1-mediated mRNA decay. Nat Struct Mol Biol 2017; 24: 534-543.
33 Sanz LA, Hartono SR, Lim YW, Steyaert S, Rajpurkar A, Ginno PA et al. Prevalent, Dynamic, and Conserved R-Loop Structures Associate with Specific Epigenomic Signatures in Mammals. Mol Cell 2016; 63: 167-178.
34 Sharpnack MF, Chen B, Aran D, Kosti I, Sharpnack DD, Carbone DP et al. Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine 2018; 27: 167-175.
35 Shen Q, Zhang Q, Shi Y, Shi Q, Jiang Y, Gu Y et al. Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation. Nature 2018; 554: 123-127.
36 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.
37 Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108: 73-112.
38 Sun Q, Csorba T, Skourti-Stathaki K, Proudfoot NJ, Dean C. R-loop stabilization represses antisense transcription at the Arabidopsis FLC locus. Science 2013; 340: 619-621.
39 Tan MH, Li Q, Shanmugam R, Piskol R, Kohler J, Young AN et al. Dynamic landscape and regulation of RNA editing in mammals. Nature 2017; 550: 249-254.
40 Wang C, Zou J, Ma X, Wang E, Peng G. Mechanisms and implications of ADAR-mediated RNA editing in cancer. Cancer Lett 2017; 411: 27-34.
41 Yu K, Chedin F, Hsieh CL, Wilson TE, Lieber MR. R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells. Nat Immunol 2003; 4: 442-451.
42 Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ et al. ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell 2016; 19: 177-191.